<qa>  What criteria will be used to evaluate subjects with measurable disease for response after every 2 cycles ofSubjects with measurable disease will be assessed for response after every 2 cycles of therapy using RECIST 1.1 criteria. In addition, progression free survival PFS, overall survival OS and exploratory biomarkers, imaging, and thrombotic risk parameters will be evaluated. 